Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Monopar Advances ALXN1840 Rolling NDA, Extends Cash Runway into 2027

Aug 12, 2026, 9:34 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Rolling NDA and RPD designation are direct regulatory catalysts; combined with positive clinical data and a clear 2027 runway, the stock could rerate on near-term milestones and potential PRV monetization.

AI summary

What happened, with direct paths to the underlying reporting

Monopar reported Q2 2026 results and highlighted a rolling NDA submission for ALXN1840 in Wilson disease, plus Rare Pediatric Disease designation. The company also showcased positive Phase 3 FoCus data and updated commercial leadership, strengthening commercialization readiness with a $134.3 million cash balance, funding operations into 2027. Near-term catalysts include NDA progress, potential PRV value, and continued program advancement.

Rolling NDA for ALXN1840 in Wilson disease initiated; submission expected in months.
FDA Rare Pediatric Disease designation granted to ALXN1840 on June 30, 2026.
Q2 2026 cash balance $134.3M; runway through 12/31/2027.
Phase 3 FoCus data show greater neurologic benefit versus standard of care.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Monopar Advances ALXN1840 Rolling NDA, Extends Cash Runway into 2027

Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?